Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.
News|Articles|July 31, 2026
The 3 Perspectives of 340B: Legal, Safety-Net, and Purchaser
Author(s)Brian Nowosielski
Based on discussions from a recent webinar debate on the 340B Drug Pricing Program, we’re revealing how differently key stakeholders see a program that pharmacists participate in every day.
Advertisement
Advertisement
When health policy experts squared off in a recent webinar, titled “The Great 340B Debate,” the disagreement was not about whether safety-net care matters; it was about whether 340B is the right vehicle for funding it. For pharmacists managing 340B workflows daily, understanding the full landscape means hearing more than one side.
Related to this article
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
In this episode, Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, explore rhythms, routines and how they can make or break pharmacy team members.
Vanessa Slowey lays the ground for where AI and automation are impacting pharmacy practice today and discusses what innovations are still expected.
Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.
Advertisement
Advertisement